CONFERENCES

International Conference on Prehypertension, Hypertension, Metabolic Disorders and Cardiovascular Disease

International Conference on Prehypertension, Hypertension, Metabolic Disorders and Cardiovascular Disease (PreHT, HT & CMS) is an annual event to deal with all aspects related to early diagnosis of prehypertension, hypertension, metabolic disorders and cardiovascular disease, with topics ranging from innovative technologies to target organ damage. The event is aimed at bringing together professionals from the fields of hypertension, cardiology, nephrology, endocrinology, internal medicine and more, and provides a forum for sharing knowledge and collaborating to identify trends within the field.

7th PreHT, HT & CMS Conference 2020

Date

Nov 20, 2020 - Nov 22, 2020

Location

Online

This event includes discussions on new mechanisms of cardiovascular damage development, novel methods of diagnosis, and new therapeutic approaches. 

See related presentations

6th PreHT, HT & CMS Conference 2019

Date

Feb 28, 2019 - Mar 03, 2019

Location

Vilnius, Lithuania

This event includes a discussion on lifestyle changes, such as diet, exercise, quitting smoking, and weight loss, as the cornerstone in the prevention and management of prehypertension, hypertension, metabolic disorders, and cardiovascular disease.

See related presentations

PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
​
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.